<style type="text/css">body .wpex-vc-row-stretched, body .vc_row-o-full-height { visibility: visible; }</style> skip to Main Content

News

Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference

TEL AVIV, Israel, Sept. 27, 2018 /PRNewswire/ --  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, announced today that Galmed management will provide a corporate update at three upcoming investor conferences in New York City: Cantor Global Healthcare Conference (October 1-3),  the ROTH Battle of the NASH Thrones Investor Conference (October 17), and the Stifel Healthcare Conference (November 13-14). 

Galmed Pharmaceuticals Logo

Cantor Global Healthcare Conference:
Date: Tuesday, October 2
Time: 9:45am Eastern Time
Location: InterContinental New York Barclay Hotel, Grand Ballroom 2

ROTH Battle of the NASH Thrones Investor Conference:
Date: Wednesday, October 17
Time: 8:00am Eastern Time
Location: Park Hyatt New York Hotel

Stifel Healthcare Conference:
This conference will take place November 13-14 in New York. Details of time and location of Galmed's presentation will be published at http://galmedpharma.investorroom.com/events when available.

About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH. Galmed recently announced top-line results of the ARREST Study, a global, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase IIb meeting with the FDA to discuss the results of the ARREST Study and a Phase III study protocol, with a view to initiating a Phase III clinical study of Aramchol in 2019.

 

 

SOURCE Galmed Pharmaceuticals Ltd.

For further information: Timothy McCarthy, LifeSci Advisors, LLC, 212-915-2564, tim@lifesciadvisors.com; Guy Nehemya, Vice President, Operations, Galmed Pharmaceuticals Ltd., guy@galmedpharma.com
Back To Top